Systemic

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Retrieved on: 
수요일, 5월 27, 2020
Medical specialties, Medicine, Autoimmune diseases, Health, RTT, Cutaneous lupus erythematosus, Connective tissue diseases, Rheumatology, Systemic lupus erythematosus, Lupus erythematosus, Systemic, Arthritis

The RESOLVE-1 Phase 3 trial is a multinational study evaluating the efficacy and safety of lenabasum in systemic sclerosis.

Key Points: 
  • The RESOLVE-1 Phase 3 trial is a multinational study evaluating the efficacy and safety of lenabasum in systemic sclerosis.
  • ACR-CRISS was also the primary endpoint in the preceding Phase 2 study recently published in Arthritis & Rheumatology .
  • Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus.
  • Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus.

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

Retrieved on: 
수요일, 4월 29, 2020
Systemic, Carboxylic acids, Phenols, Genentech

The paper [doi:10.1002/art.41294] is titled Safety and efficacy of lenabasum in a Phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis.

Key Points: 
  • The paper [doi:10.1002/art.41294] is titled Safety and efficacy of lenabasum in a Phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis.
  • Efficacy and safety of lenabasum in systemic sclerosis are currently being evaluated in Corbus global, 365-subject, RESOLVE-1 Phase 3 study.
  • Lenabasum has demonstrated promising activity in animal models of skin and lung inflammation and fibrosis in systemic sclerosis (SSc).
  • Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus.

Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027 - ResearchAndMarkets.com

Retrieved on: 
화요일, 4월 21, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Autoimmune diseases, Kidney diseases, Autoantibodies, RTT, Systemic lupus erythematosus, William Osler, Lupus erythematosus, Nephritis, Lupus nephritis, Systemic

The "Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global SLE and LN market.

Systemic Sclerosis Pipeline Insights, 2020 - ResearchAndMarkets.com

Retrieved on: 
월요일, 4월 20, 2020
Managed care, Pharmaceutical, Health, Organ systems, Autoimmune diseases, Anatomy, Medical specialties, Mucinoses, Systemic scleroderma, Systemic, Monoclonal antibodies

Systemic Sclerosis Pipeline Insights, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Systemic Sclerosis market.

Key Points: 
  • Systemic Sclerosis Pipeline Insights, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Systemic Sclerosis market.
  • A detailed picture of the Systemic Sclerosis pipeline landscape is provided, which includes the disease overview and Systemic Sclerosis treatment guidelines.
  • The assessment part of the report embraces in-depth Systemic Sclerosis commercial assessment and clinical assessment of the Systemic Sclerosis pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Systemic Sclerosis emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Systemic Sclerosis?

Global Systemic Lupus Erythematosus Report, 10-Year Forecasts, 7MM Coverage and Detailed Pipeline Product Profiles

Retrieved on: 
수요일, 4월 1, 2020
Medical specialties, Medicine, Autoimmune diseases, Organ systems, Cutaneous lupus erythematosus, Lupus erythematosus, Systemic lupus erythematosus, Anti-SSA/Ro autoantibodies, Systemic, Neuropsychiatric systemic lupus erythematosus, Neonatal lupus erythematosus

According to the American College of Rheumatology Systemic lupus erythematosus, referred to as SLE or lupus, is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs.

Key Points: 
  • According to the American College of Rheumatology Systemic lupus erythematosus, referred to as SLE or lupus, is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs.
  • The Systemic Lupus Erythematosus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
  • Among 7MM, the United States has the highest prevalent population of Systemic Lupus Erythematosus with about 259,474 cases in 2017.
  • The report covers a descriptive overview of the Systemic Lupus Erythematosus, explaining its causes, risk factors, pathophysiology, and diagnosis.

Global Systemic Lupus Erythematosus Treatment Market Analysis, Size, Share, Growth, Trends & Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
월요일, 2월 10, 2020
Health, Pharmaceutical, Cutaneous lupus erythematosus, Autoimmune diseases, Medical specialties, Medicine, Organ systems, Lupus erythematosus, Systemic lupus erythematosus, Systemic, Anti-SSA/Ro autoantibodies

The "Systemic Lupus Erythematosus Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Lupus Erythematosus Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The report provides the overall market revenue of the global systemic lupus erythematosus treatment market for the period of 2017-2027, considering 2018 as the base year and 2027 as the forecast year.
  • The report also provides the compound annual growth rate (CAGR %) of the global systemic lupus erythematosus treatment market from 2019 to 2027..
  • Moreover, the report throws light on the changing competitive dynamics in the global systemic lupus erythematosus treatment market.

Global Systemic Inflammatory Response Syndrome Treatment Market to 2027- Drivers, Restraints & Opportunities - ResearchAndMarkets.com

Retrieved on: 
목요일, 2월 6, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Health, Systemic, Autoimmune diseases, Immunology, Inflammation, Sjögren syndrome

Additionally, the report sheds light on the changing competitive dynamics in the global systemic inflammatory response syndrome treatment market.

Key Points: 
  • Additionally, the report sheds light on the changing competitive dynamics in the global systemic inflammatory response syndrome treatment market.
  • These indices serve as valuable tools for existing market players as well as for entities interested in entering the global systemic inflammatory response syndrome treatment market.
  • Which factors will hamper the growth of the global systemic inflammatory response syndrome treatment market during the forecast period?
  • What are the opportunities in the global systemic inflammatory response syndrome treatment market?

Pipeline Review of Systemic Sclerosis - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
목요일, 1월 30, 2020
Biotechnology, Pharmaceutical, Health, Organ systems, Autoimmune diseases, Mucinoses, Medicine, Anatomy, Connective tissue diseases, Systemic scleroderma, Scleroderma, Sclerosis, Systemic

The "Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Retrieved on: 
월요일, 11월 11, 2019
Autoimmune diseases, Medical specialties, Medicine, Organ systems, Rheumatology, Lupus erythematosus, Systemic

These data are being presented at the American College of Rheumatology (ACR) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia.

Key Points: 
  • These data are being presented at the American College of Rheumatology (ACR) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia.
  • Mean Forced Vital Capacity (FVC) % predicted declined -2.0% from study start through latest data cut in September 2019.
  • Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
  • Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus.

AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis

Retrieved on: 
목요일, 10월 24, 2019
Immune system disorders, Mastocytosis, Protein kinase inhibitors, Masitinib, Systemic

Company to host live webcast on November 20, 2019 on indolent systemic

Key Points: 
  • Company to host live webcast on November 20, 2019 on indolent systemic
    AB Science SA (NYSE Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate the Phase 3 confirmatory study evaluating masitinib in indolent systemic mastocytosis.
  • This observation is important, given that indolent systemic mastocytosis is a chronic condition that requires lifelong management.
  • Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
  • Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.